Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions
- PMID: 35941035
- DOI: 10.1016/j.vaccine.2022.07.022
Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions
Conflict of interest statement
Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Emily Burger, Iacopo Baussano, Jane J. Kim, Jean-Francois Laprise, John T. Schiller, Kiesha Prem, Marc Brisson, Mark Jit and Ruanne Barnabas report funding grants from the Single Dose HPV Vaccine Consortium, which is funded by the Bill & Melinda Gates Foundation to synthesize existing evidence and evaluate new data around single-dose HPV vaccination. Karen Canfell reports an investigator-initiated trial of cervical screening run by the ACPCC, a government-funded not-for-profit charity, and the trial receives infrastructure support from the Australian government and equipment and a funding contribution from Roche Molecular Diagnostics, USA; and she also reports support for an implementation program in the Western Pacific which has received support from the Minderoo Foundation and the Frazer Family Foundation and equipment donations from Cepheid Inc. Ruanne Barnabas reports non-financial support from Regeneron Pharmaceuticals. Mark Jit is an editorial board member of Vaccine.
Comment on
-
Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination regimen in a high-income country setting: An analysis in the United Kingdom.Vaccine. 2022 Mar 25;40(14):2173-2183. doi: 10.1016/j.vaccine.2022.02.067. Epub 2022 Feb 26. Vaccine. 2022. PMID: 35232593
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical